Blood and Other Products of Human Origin
WHO develops norms, standards, technical guidance and high-level strategic recommendations and provides scientific assessment of current and emerging threats on ensuring availability, safety and quality of blood products and works to improve global access to transplantation of human organs and tissues. The work supports strengthening of country and regional capacity for the supply of quality-assured safe blood products and transplant services improving access to these life-saving treatments.
Partners and Collaborators
Networks and Advisory groups
Other Relevant Teams/Programmes
WHO Collaborating Centres
WHO collaborating centres are institutions such as research institutes, parts of universities or academies, which are designated by the Director-General to carry out activities in support of the Organization's programmes. Currently there are 6 WHO collaborating centres in blood and transplantation.
NSAs in Official Relations
Non-State Actors (NSAs) are nongovernmental organizations, private sector entities, philanthropic foundations and academic institutions. “Official relations” is a privilege that the Executive Board may grant to NSAs that have had and continue to have a sustained and systematic engagement in the interest of the Organization. The aims and activities of all these entities shall be in conformity with the spirit, purposes and principles of WHO’s Constitution, and they shall contribute significantly to the advancement of public health. Currently there are 5 NSAs in official relations with WHO in blood and transplantation.
Latest Publications
All →
Guidance on implementing patient blood management to improve global blood health status
Incorporating expertise from peers working in countries where health care faces extreme resource constraints, attention is paid to how PBM processes...
Implementing cross-border transfer of domestic plasma to obtain plasma-derived medicinal products: policy...
The document provides recommendations on legal, regulatory and policy conditions for assuring the quality of plasma for fractionation and protecting the...
This document provides guidance on the activities needed to implement a functioning quality system in the BE, withinformation on the technical resources...
Guidance on ensuring a sufficient supply of safe blood and blood components during emergencies
This guidance document has been produced by the World Health Organization (WHO) to assist blood services in the development of national plans to respond...
User guide for navigating resources on stepwise implementation of haemovigilance systems
WHO recognizes the importance of haemovigilance, systematic blood safety surveillance, to identify and prevent occurrence or recurrence of transfusion-related...
Educational modules on clinical use of blood
Blood transfusion is an essential part of patient care. When used correctly, it saves lives and improves health. However, blood transfusion carries a...
In the past four decades, increased awareness of the inherent risks of transfusion has resulted in major initiatives to mitigate those risks through...
Guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries...
Several plasma-derived medicinal products (PDMPs) are included in the WHO Model List of Essential Medicines, highlighting them as medications considered...
Multiple barriers to the safety and availability of blood components for transfusion were identified in the 2015 Global Database on Blood Safety, many...
Our Team
Dr. Yuyun Maryuningsih
Team lead - Blood and Other Products of Human Origin
Email: maryuningsihy@who.int